Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. by Turner, Nicholas C et al.
Thomas Jefferson University
Jefferson Digital Commons
Department of Medicine Faculty Papers Department of Medicine
10-22-2015
Palbociclib in Hormone-Receptor-Positive
Advanced Breast Cancer.
Nicholas C Turner
Royal Marsden Hospital, London, United Kingdom
Cynthia Huang Bartlett
Pfizer, New York, NY, United States
Massimo Cristofanilli
Thomas Jefferson University, Philadelphia, PA, United States, Massimo.Cristofanilli@jefferson.edu
Let us know how access to this document benefits you
Follow this and additional works at: http://jdc.jefferson.edu/medfp
Part of the Other Medical Specialties Commons
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas
Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly
publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and
interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in
Department of Medicine Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact:
JeffersonDigitalCommons@jefferson.edu.
Recommended Citation
Turner, Nicholas C; Huang Bartlett, Cynthia; and Cristofanilli, Massimo, "Palbociclib in Hormone-
Receptor-Positive Advanced Breast Cancer." (2015). Department of Medicine Faculty Papers. Paper
156.
http://jdc.jefferson.edu/medfp/156
n engl j med 373;17 nejm.org october 22, 20151672
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
c o r r e s p o n d e n c e
Palbociclib in Hormone-Receptor–Positive Advanced  
Breast Cancer
To the Editor: In the PALOMA3 study, Turner et 
al. (July 16 issue)1 report that the addition of pal-
bociclib to fulvestrant improved progression-free 
survival as compared with fulvestrant alone in pa-
tients with advanced breast cancer, with similar 
discontinuation rates because of adverse effects 
(2.6% and 1.7%, respectively). However, molecu-
larly targeted therapies have moderate toxic effects 
that may become unacceptable over the long term 
and result in a deterioration in the quality of life, 
as shown in a previous report.2,3 The PALOMA1 
study, a previous phase 2 trial of palbociclib with 
a median follow-up of approximately 30 months, 
showed that the combination of palbociclib and 
letrozole, as compared with letrozole alone, was 
associated with higher rates of discontinuation 
(11% vs. 2%) and dose interruption (33% vs. 4%) 
because of adverse effects.4 Furthermore, the rate 
of pulmonary embolism in the PALOMA1 study 
was higher than that in the PALOMA3 study (4% 
vs. 0.9%). Thus, because the authors report the 
results of a predetermined interim analysis with 
a median observation period of only 5.6 months, 
it is possible that further follow-up may reveal 
long-term toxic effects that disturb the regular 
administration of the combination therapy or 
hamper the use of subsequent therapies.
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The authors reply: In the PALOMA3 study, on 
the advice of the independent data and safety 
monitoring committee, we reported substantial 
efficacy for palbociclib in combination with ful-
vestrant at the time of the interim analysis. The 
median of 5.6 months of follow-up at the interim 
analysis was too short a period to assess possible 
long-term adverse effects associated with palbo-
ciclib. Ozaki and colleagues note that molecularly 
targeted therapies may have long-term low-grade 
toxic effects and suggest that such adverse events 
can lead to a reduced quality of life. In contrast, 
in PALOMA3, patients’ quality of life was main-
tained among those receiving palbociclib–fulves-
trant as compared with substantial deterioration 
among those receiving fulvestrant alone.
Follow-up continues in the PALOMA3 study, 
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and we will be updating efficacy and safety 
data. The first updated data, which were collect-
ed in March 2015 with a median follow-up of 
8.9 months, showed that the rate of pulmonary 
embolism remained low (0.9%) among patients 
treated with palbociclib. Moreover, the discon-
tinuation rate because of adverse effects among 
patients receiving palbociclib remained at 4.0%, 
as compared with a rate of 1.7% for those receiv-
ing fulvestrant alone. These findings support the 
long-term safety of palbociclib that was reported 
in the smaller PALOMA1 study.1
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Somatic Mutations and Clonal Hematopoiesis  
in Aplastic Anemia
To the Editor: In their study involving 439 pa-
tients with aplastic anemia, Yoshizato and col-
leagues (July 2 issue)1 bring us closer to under-
standing clonal hematopoiesis in patients with this 
disease. However, a key conceptual aspect of the 
study is that the investigators prescreened patients 
for somatic mutations in genes that are mutated 
in myeloid cancers using targeted sequencing, 
followed by whole-exome sequencing, mainly in 
patients with mutations in the targeted genes. Fur-
thermore, the study population included those 
with the post–aplastic anemia myelodysplastic syn-
drome (MDS), which further biased the identified 
pattern of clonal hematopoiesis toward MDS-asso-
ciated mutations. Using an unbiased approach of 
comparative whole-exome sequencing of bone 
marrow and skin DNA, we recently found so-
matic mutations in 73% of 22 patients with 
aplastic anemia who were not prescreened with 
targeted sequencing.2 None of the patients who 
were included in our study had evidence of mye-
lodysplasia. Somatic mutations were significantly 
enriched in pathways of immunity, whereas only 
9% of the patients carried mutations associated 
with MDS. Further studies using unbiased ap-
proaches with long-term follow-up will help to 
capture the full spectrum and biologic signifi-
cance of clonal hematopoiesis in aplastic anemia.
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To the Editor: Yoshizato et al. report that so-
matically mutated clones are detectable in 47% 
of patients with aplastic anemia. The single most 
frequently mutated gene was DNMT3A (in 8.4% 
of patients), which, along with ASXL1, was as-
sociated with a poorer response to immunosup-
pressive therapies than were mutations in PIGA 
or BCOR/BCORL1 and with worse overall survival. 
However, we notice that DNMT3A mutations were 
almost twice as frequent among Japanese patients 
as among U.S. patients. In the Japanese patients, 
whole blood was compared with buccal-smear 
DNA; in the U.S. patients, granulocytes were 
compared with CD3+ T cells. Since DNMT3A-
mutated clones are frequently detectable in both 
myeloid and lymphoid cells of healthy older per-
sons,1 the significance of their occurrence in pa-
tients with aplastic anemia, as well as the discor-
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